Mandar Ghatnekar Joins Biocon as Chief Technology Officer

Previously Global Head of IT & Digital Transformation at Biocon Biologics since April 2023, Ghatnekar led post-merger IT integration, AI/cloud adoption, and supply chain automation to streamline biosimilars access globally.

Global pharma giant Biocon has named Mandar Ghatnekar as its new Chief Technology Officer (CTO). The leadership shuffle supports the company's efforts in digital innovation and enterprise technology across its Bengaluru-based operations.

Ghatnekar moves to this position after working as Global Head of IT and Digital Transformation at Biocon Biologics. There, he directed company-wide digital projects, including post-merger IT integration, and accelerated the adoption of AI, cloud computing, and automation tools.

These initiatives streamlined supply chains, optimized procurement processes, and enhanced biosimilars development, ultimately improving operational efficiency and patient outcomes.

With over 20 years of experience in digital transformation and enterprise technology, Ghatnekar holds a Master's in computer science from the University of Pune. His expertise spans enterprise architecture, cybersecurity, data analytics, and AI/ML implementation.

He has a proven track record of building scalable technology systems and managing large-scale transformation efforts in the life sciences.

Before joining Biocon, he held senior leadership roles at Accenture and Johnson & Johnson, where he gained deep knowledge in cloud migration, ERP optimization, and healthcare IT solutions.

At Accenture, he led digital strategy consulting for pharma clients, pioneering predictive analytics for manufacturing. His time at Johnson & Johnson focused on global data platforms and compliance-driven tech stacks, driving cost savings and innovation in drug delivery systems.

His appointment aligns with Biocon's strategic push amid India's booming biotech-healthtech convergence, targeting faster R&D timelines and personalized therapies. As life sciences companies increasingly invest in digital platforms, data-driven decision-making, and advanced tech infrastructures like Industry 4.0 digital twins and hybrid cloud models, Ghatnekar's vision will unify Biocon's tech ecosystem.

This positions the company to accelerate its global biosimilars pipeline, enhance regulatory compliance, and compete effectively in a market projected to reach $150 billion by 2030.

Stay tuned for more such updates on Digital Health News